Walleye Capital LLC Unicycive Therapeutics, Inc. Call Options Transaction History
Walleye Capital LLC
- $20.4 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding UNCY
# of Institutions
31Shares Held
59.9MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA11.4MShares$6.71 Million1.76% of portfolio
-
Great Point Partners LLC Greenwich, CT11MShares$6.48 Million3.87% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$5.9 Million1.9% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT9.39MShares$5.54 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3 Million0.56% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.88M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...